HCID 57720218, 화합물 → HCID 57720313, 화합물

HRID 1985849노트

반응식

HRID 1985849 반응식
C(OC([NH:8][CH2:9][CH2:10][CH2:11][NH:12][C:13]([CH2:15][O:16][C:17]1[CH:18]=[C:19]([CH:40]=[CH:41][CH:42]=1)[CH2:20][NH:21][C:22]1[N:26]([C@@H:27]2[O:33][C@H:32]([CH2:34][OH:35])[C@@H:30]([OH:31])[C@H:28]2[OH:29])[C:25]2[CH:36]=[CH:37][CH:38]=[CH:39][C:24]=2[N:23]=1)=[O:14])=O)(C)(C)C>Cl.C(O)C>[NH2:8][CH2:9][CH2:10][CH2:11][NH:12][C:13]([CH2:15][O:16][C:17]1[CH:18]=[C:19]([CH:40]=[CH:41][CH:42]=1)[CH2:20][NH:21][C:22]1[N:26]([C@@H:27]2[O:33][C@H:32]([CH2:34][OH:35])[C@@H:30]([OH:31])[C@H:28]2[OH:29])[C:25]2[CH:36]=[CH:37][CH:38]=[CH:39][C:24]=2[N:23]=1)=[O:14]

참가 물질

3

반응물 1

HCID 57720218HCID 57720218, 화합물

생성물 1

HCID 57720313HCID 57720313, 화합물수율 72.4%

시약·촉매·용매 1

HCID 21887872Ethanol hydrochloride용매

실험 절차

2-{3-[(3-t-Butoxycarbonylaminopropylcarbamoyl)methoxy]benzylamino}-1-(β-D-ribofuranosyl)-1H-benzimidazole (15 mg) was dissolved in 22% hydrochloride-ethanol solution, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by preparative reverse phase column chromatography (Shiseido CAPSELL PAC C18UG80, 5 μm, 20×50 mm, flow rate 30 mL/minutes linear gradient, water/methanol=90/10-10/90) to give the title compound (9 mg).

후처리

  1. concentrationThe reaction mixture was concentrated under reduced pressure
  2. customthe obtained residue was purified by preparative reverse phase column chromatography (Shiseido CAPSELL PAC C18UG80, 5 μm, 20×50 mm, flow rate 30 mL/minutes linear gradient, water/methanol=90/10-10/90)

출처 및 근거

ORD 기록
ord-a18eec13e7d440dbafd25f187010e757
출처 데이터셋
uspto-grants-2009_06
특허 번호
US07547680B2

반응 노트

불러오는 중…